1
Clinical Trials associated with [111In]In-DOTA-ANTI-CEA antibody(Radboud University Medical Center)A Phase I/II Study to Evaluate the Safety and Feasibility of Multimodal Imaging Using a Dual-labeled Anti-CEA Antibody in Patients With Rectal or Pancreatic Cancer
Most digestive cancers show (over)expression of the tumour marker carcinoembryonic antigen (CEA). Therefore, interest in CEA-targeting tracers has increased over the past years. CEA-targeting tracers can be used for preoperative, intra-operative and postoperative imaging purposes. This study focusses on both preoperative and intraoperative multimodal imaging and image-guided surgery in patients with rectal cancer or pancreatic cancer.
100 Clinical Results associated with [111In]In-DOTA-ANTI-CEA antibody(Radboud University Medical Center)
100 Translational Medicine associated with [111In]In-DOTA-ANTI-CEA antibody(Radboud University Medical Center)
100 Patents (Medical) associated with [111In]In-DOTA-ANTI-CEA antibody(Radboud University Medical Center)
100 Deals associated with [111In]In-DOTA-ANTI-CEA antibody(Radboud University Medical Center)